Experimental lymphoma drug CPO107 tested in small early trial
NCT ID NCT04853329
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a new drug called CPO107 in 7 people with advanced CD20-positive Non-Hodgkin lymphoma who had no other good treatment options. The goal was to find a safe dose and see how the body handles the drug. The trial was stopped early, so we have limited information about whether it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CPO107 (a bispecific fusion protein targeting CD20 and CD47)
- What this could lead to
- If successful, this could point toward a new treatment option for patients with advanced Non-Hodgkin lymphoma who have run out of standard therapies.
- What could go wrong
- This was a very early (Phase 1), small trial (only 7 participants) that was terminated early, so results are limited. It is unclear if CPO107 is safe or effective, and it may not work in larger groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL PROLYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novant Health
Charlotte, North Carolina, 28204, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?